Pathophysiology and mechanisms of radiopharmaceutical localization

The Pathophysiologic Basis of Nuclear Medicine: Second Edition

Volumn , Issue , 2006, Pages 29-49

  Vallabhajosula, Shankar ^a   Owunwanne, Azu ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36348988153     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-47953-6_2     Document Type: Chapter

References (83)

1. Wagner HN Jr (1995) Nuclear medicine: what it is and what it does. In: Wagner HN Jr, Szabo Z, Buchanan JW (eds) Principles of nuclear medicine. WB Saunders, Philadelphia, pp 1-8
2. Virchow R (1958) Disease, life and man. Stanford University Press, Stanford, Calif.
3. McCance KL, Huether SE (1998) Pathophysiology. The biologic basis for disease in adults and children, 3rd edn. Mosby-Year Book, St. Louis
4. Cotran RS, Kumar V, Collins T (1999) Robbins pathologic basis of disease, 6th edn. WB Saunders, Philadelphia
5. Wagner HN Jr (1995) The diagnostic process. In: Wagner HN Jr, Szabo Z, Buchanan JW (eds) Principles of nuclear medicine. WB Saunders, Philadelphia, pp 9-17
6. Krasnow AZ, Hellman RS, Timins ME, et al (1997) Diagnostic bone scanning in oncology. Semin Nucl Med 27: 107-141
7. Delmon-Moingeon LI, Piwinca-Wormas D, Van den Ab-beele AD, Holman BL, Davison A, Jones AG (1990) Uptake of the cation hexakis (2- methoxyisobutylisonitrile)-tech-netium-99m by human carcinoma cell lines in vitro. Cancer Res 50:2198-2202
8. Piwnica-Worms D, Kronauge JF, Chiu ML (1990) Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells. Mito-chondrial and plasma membrane potential dependence. Circulation 82:1826-1838
9. Arbab AS, Koizumi K, Toyama K, Araki T (1996) Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 37:1551-1556
10. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer R, Croop JM (1993) Functional imaging of multi-drug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977-984
11. Hendrikse NH, et al (1998) 99mTc-sestamibi is a substrate for P-glycoprotein and the multi-drug resistance associated protein. Br J Cancer 77:353-358
12. Tsan MF, Scheffel U (1986) Mechanism of gallium-67 accumulation in tumors. J Nucl Med 27:1215-1219
13. Weiner RE (1996) The mechanism of 67 Ga localization in malignant disease. Nucl Med Biol 23:745-751
14. Vallabhajosula SR, Harwig JF, Siemsen JK, et al (1980) Ra-diogallium localization in tumors: blood binding and transport and the role of transferrin. J Nucl Med 21: 650-656
15. Hayes RL, Rafter JJ, Byrd BL, Carlton JE (1981) Studies of the in vivo entry of Ga-67 into normal and malignant tissue. J Nucl Med 22:325-332
16. Mueckler M (1994) Facilitative glucose transporters. Eur J Biochem 219:713-725
17. Schwenk M (1980) Transport systems of isolated hepato-cytes: studies on the transport of biliary compounds. Arch Toxicol 44:113-126
18. Okuda H, Nunes R, Vallabhajosula S, et al (1986) Studies of the hepatocellular uptake of the hepatobiliary scintiscan-ning agent 99mTc-DISIDA. J Hepatol 3:251-259
19. Weich HF, Strauss HW, Pitt B (1977) The extraction of thal-lium-201 by the myocardium. Circulation 56:188
20. Sessler M, Maul FD, Geck P, Munz D, Hor G (1982) Kinetics and mechanism of thallium uptake in malignant tumors in vivo and in vitro. In: Raynaud C (ed) 3rd World Congress of Nuclear Medicine and Biology, August 29-September 2, Paris. Nucl Med Biol Proc 1982:2281-2284
21. Sessler MJ, Geck P, Maul FD, et al (1986) New aspects of cellular Tl-201 uptake: co-transport is the central mechanism of ion uptake. Nucl Med 25:24-27
22. Eshima D, Taylor A (1992) Tc-99m mercaptoacetyltriglyci-ne (Tc-99m MAG3): update on the new Tc-99m renal tubular function agent. Semin Nucl Med 22:61-73
23. Eshima D, Taylor A (1992) Semin Nucl Med 22:61-73, and chapter 73, Red Book)
24. Alazraki NP, Eshima D, Eshima LA, et al (1997) Lymphos-cintigraphy, the sentinel node concept, and the intraopera-tive gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 27:55-67
25. Larson SM, Rasey JS, Allen DR, et al (1980) Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 64:41-53
26. Sohn MH, Jones BJ, Whiting Jr JH, et al (1993) Distribution of gallium-67 in normal and hypotransferrinemic tumor-bearing mice. J Nucl Med 34:2135-2143
27. Ido T, Wan C-N, Fowler JS, et al (1977) Fluorination with F2. A convenient synthesis of 2-deoxy-2-fluoro-D-glucose. J Org Chem 42:2341-2342
28. Som P, Atkins HL, Bandoypadhyay D, et al (1980) A fluori-nated glucose analog, 1-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21:670-675
29. 18F]2-deoxy-2-fluoro-D-glucose. J Nucl Med 19:1154-1161
30. Kubota R, Yamada S, Kubota K, et al (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiographic comparison with FDG. J Nucl Med 33:1872-1980
31. Vaalburg W, Coenen HH, Crouzel C, et al (1992) Amino acids for the measurement of protein synthesis in vivo by PET. Nucl Med Biol 19:227-237
32. 18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol 20:895-899
33. 18F]1-amino-3-fluorocyclobutane-1-carbo-xylic acid to image brain tumors. J Nucl Med 40:331-338
34. 18F]fluorethyltyrosine for tumor imaging. J Nucl Med 40:205-212
35. Nunn A, Linder K, Strauss HW (1995) Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 22:265-280
36. Rasey JS, Koh WJ, Evans ML, et al (1996) Quantifying regional hypoxia in tumors with positron emission tomography: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36:417-428
37. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40:177-183
38. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 65:90-95
39. Ballinger JR, Kee JWM, Rauth AM (1996) In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimid-azole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 37:1023-1031
40. Cook GJR, Houston S, Barrington SF, Fogelman I (1998) Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 39:99-103
41. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
42. Vallabhajosula SR, Harwig JF, Wolf W (1982) Effect of pH on tumor cell uptake of radiogallium in vitro and in vivo. Eur J Nucl Med 7:462-468
43. 3H] labeling index in human solid tumors. Cancer Res 34:1376-1380
44. Goethals P, Lameire N, van Eijkeren M, et al (1996) Methyl-carbon-11 thymidine for in vivo measurement of cell proliferation. J Nucl Med 37:1048-1052
45. Kassis AI, Adelstein SJ (1996) Preclinical animal studies with radioiododeoxyuridine. J Nucl Med 37 [Suppl]:10s-12s
46. O'Donoghue JA (1996) Strategies for selective targeting of Auger electron emitters to tumor cells. J Nucl Med 37 [Suppl]:3s-6s
47. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niz-nik H, Srikant CB (1995) Minireview: the somatostatin receptor family. Life Sci 57:1249-1265
48. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nuc Med Mol Imaging 31:1659-1672
49. Reubi JC, Laissue J, Krenning EP, Lamberts SWJ (1992) So-matostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implication. J Steroid Biochem Mol Biol 43:27-35
50. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731
51. Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Ra-dosavljevic M (1997) Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? Eur J Clin Invest 27:645-647
52. 3]oc-treotide, a promising somatostatin analog for radionuclide therapy. Eur J Nucl Med 24:368-371
53. 3]-Octreotide (SMT487) eradicates experimental rat pancreatic CA 20948 tumors. Eur J Nucl Med 25:668-674
54. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P (1998) Indium-111-DOTA-lanreotide: biodistribution, safety and tumor dose in patients evaluated for somatostatin receptor-mediated radiotherapy. J Nucl Med 39:1928-1936
55. 99mTc-P829. J Nucl Med 37:1016-1022
56. Reubi JC (1995) In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 36:1846-1853
57. Virgolini I, Raderer M, Kurtaran A, et al (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331:1116-1121
58. Virgolini I, Yang Q, Li S, et al (1994) Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 54:690-700
59. Katzenellenbogen JA (1995) Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med 36 [Suppl]:8s-13s
60. 123I]iodovinyloestradiol and its 11-methoxy derivative evaluated for their estrogen receptor binding in human MCF-7 cells and rat uterus, and their distribution in immature rats. Eur J Nucl Med 23:295-307
61. Wieland DM, Swanson DP, Brown LE, Beierwalters WH (1979) Imaging the adrenal medulla with an I-131-labeled anti-adrenergic agent. J Nucl Med 20:155-158
62. Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM (1984) Comparison of sodium dependency of uptake of metaiodobezylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 26:539-546
63. Beierwalters WH, Weiland DM, Yu T, Swanson D, Mosley S (1978) Adrenal imaging agents. Rationale, synthesis, formulation and metabolism. Semin Nucl Med 8:5-21
64. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465
65. Goedemans WT, Panek KJ, Ensing GJ, et al (1990) A new simple method for labeling of proteins with Tc-99m 1-imi-no-4-mercaptobutyl groups. In: Nicolini M, Bandolini G, Mazzi U (eds) Technetium and rhenium in chemistry and nuclear medicine, vol 3. Cortina International, Verona; Raven Press, New York, pp 595-604
66. Joiris E, Bastin B, Thornback JR (1990) A new method for labeling of monoclonal antibodies, fragments and other proteins with technetium-99m. In: Nicolini M, Bandolini G, Mazzi U (eds) Technetium and rhenium in chemistry and nuclear medicine, vol 3. Cortina International, Verona; Raven Press, New York, pp 609-614
67. Fritzberg AR, Abrams PG, Beaunier PC, et al (1988) Specific and stable labeling of antibodies with technetium-99m with a diamidedithiolate chelating agent. Proc Natl Acad Sci USA 85:4025-4029
68. Knox S, Goris M, Trisler K, et al (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470
69. Stoldt HS, Aftab F, Chinol M, et al (1997) Pretargeting strategies for radioimmunoguided tumor localization and therapy. Eur J Cancer 33:186-192
70. Hnatowich DJ, Virzi F, Rusckowski M (1987) Investigations of avidin and biotin for imaging applications. J Nucl Med 28:1294-1302
71. Paganelli G, Magnani P, Zito F, et al (1991) Three-step monoclonal antibody tumor targeting in carcinoembryo-nic antigen-positive patients. Cancer Res 51:5960-5966
72. Younes CK, Boisgard R, Tavitian B (2002) Labelled oligo-nucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr Pharm Des 8:1451-1466
73. Zhang YR, Zhang YX, Cao W, Lan XL (2005) Uptake kinetics of 99mTc-MAG3-antisense oligonucleotide to PCNA and effect on gene expression in vascular smooth muscle cells. J Nucl Med 46:1052-1058
74. Qin G, Zhang Y, Cao W, et al (2005) Molecular imaging of atherosclerotic plaques with technetium-99m-labelled an-tisense oligonucleotides. Eur J Nucl Med Mol Imaging 32: 6-14
75. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al (1994) Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med 35:1054-1063
76. 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med 42: 1766-1755
77. de Varies EF, Vroegh J, Dijkstra G, et al (2004) Synthesis and evaluation of a fluorine-18 labeled antisense oligonu-cleotide as a potential PET tracer for iNOS mRNA expression. Nucl Med Biol 31:605-612
78. Gambhir SS, Barrio JR, Herschman HR, et al (1996) Imaging gene expression: Principles and assays. J Nucl Cardiol 6:219-233
79. 14C-FIAU for imaging of HSV1-tk receptor expression: adenoviral infection vs stable transfection. Eur J Nucl Med 30:1547-1560
80. Tjuvajev JG, Finn R, Watanabe K, et al (1996) Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 56:4087-4095
81. Tjuvajev JG, Doubrovin M, Akhurst T, et al (2002) Comparison of radiolabeled nucleoside probes (FIAU, FHBG, FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 43:1072-1083
82. MacLaren DC, Gambhir SS, Satyamurthy N, et al (1999) Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 6: 758-791
83. 123I-IBZM; a potential CNS D-2 dopa-mine receptor imaging agent. J Nucl Med 30:88-94